|
RU2019118257A
(ru)
|
2012-12-03 |
2019-06-24 |
Новиммун С.А. |
Анти-cd47 антитела и способы их применения
|
|
ES2867224T3
(es)
|
2014-04-10 |
2021-10-20 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Etiquetas genéticas transgénicas y métodos de uso
|
|
PT4219687T
(pt)
|
2014-04-23 |
2024-10-02 |
Juno Therapeutics Inc |
Métodos para isolamento, cultura, e manipulação genetica de populações de células imunes para terapêutica adotiva
|
|
EP3143134B1
(en)
|
2014-05-15 |
2020-10-28 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
CN107106610A
(zh)
|
2014-10-20 |
2017-08-29 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗中的给药的组合物和方法
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
JP7162530B2
(ja)
|
2015-08-07 |
2022-10-28 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
|
|
CA3006249A1
(en)
|
2015-11-25 |
2017-06-01 |
Legochem Biosciences, Inc. |
Antibody-drug conjugates comprising branched linkers and methods related thereto
|
|
WO2017089894A1
(en)
|
2015-11-25 |
2017-06-01 |
Legochem Biosciences, Inc. |
Conjugates comprising peptide groups and methods related thereto
|
|
HRP20240795T1
(hr)
|
2015-11-25 |
2024-09-13 |
Ligachem Biosciences Inc. |
Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
|
|
US12048718B2
(en)
*
|
2016-06-07 |
2024-07-30 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft |
Chimeric antigen receptor and CAR-T cells that bind BCMA
|
|
CN111848801B
(zh)
*
|
2016-09-06 |
2022-10-11 |
上海吉倍生物技术有限公司 |
一种抗cd19抗体及其制备方法和用途
|
|
US20180142018A1
(en)
*
|
2016-11-04 |
2018-05-24 |
Novimmune Sa |
Anti-cd19 antibodies and methods of use thereof
|
|
WO2018108106A1
(zh)
*
|
2016-12-13 |
2018-06-21 |
科济生物医药（上海）有限公司 |
抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
|
|
EP4032550A3
(en)
|
2017-01-05 |
2022-10-19 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
|
|
AU2018207281B2
(en)
|
2017-01-10 |
2024-08-01 |
Precigen, Inc. |
Modulating expression of polypeptides via new gene switch expression systems
|
|
US10836810B2
(en)
|
2017-02-17 |
2020-11-17 |
Mapp Biopharmaceutical, Inc. |
Monoclonal antibodies and cocktails for treatment of ebola infections
|
|
BR112019017767A2
(pt)
|
2017-02-27 |
2020-04-07 |
Juno Therapeutics Inc |
composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
|
|
KR20250029276A
(ko)
|
2017-03-14 |
2025-03-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
극저온 보관 방법
|
|
JP7270253B2
(ja)
|
2017-03-27 |
2023-05-10 |
ナショナル ユニヴァーシティ オブ シンガポール |
ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株
|
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
|
IL269535B2
(en)
|
2017-03-29 |
2024-11-01 |
Ligachem Biosciences Inc |
Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
JOP20180042A1
(ar)
*
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
AU2018275894B2
(en)
|
2017-06-02 |
2025-04-24 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
KR102557834B1
(ko)
|
2017-06-07 |
2023-07-21 |
프레시전 인코포레이티드 |
신규의 세포 태그의 발현
|
|
EP3441471A1
(en)
*
|
2017-08-08 |
2019-02-13 |
CEVEC Pharmaceuticals GmbH |
Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
|
|
EP3664820B1
(en)
|
2017-08-09 |
2023-07-19 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
WO2019032929A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR PREPARING GENETICALLY MODIFIED CELLS
|
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
|
EP3679370A1
(en)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
|
WO2019055399A1
(en)
*
|
2017-09-12 |
2019-03-21 |
Igc Bio, Inc. |
ANTI-VEGF ANTIBODIES
|
|
CN119120527A
(zh)
*
|
2017-09-15 |
2024-12-13 |
莱蒂恩技术公司 |
用于用抗cd19免疫治疗来治疗癌症的组合物和方法
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
JP7185696B2
(ja)
*
|
2017-09-22 |
2022-12-07 |
ウーシー バイオロジクス アイルランド リミテッド |
新規な二重特異性ｃｄ３／ｃｄ１９ポリペプチド複合体相互参照
|
|
EP3684816B1
(en)
*
|
2017-09-22 |
2024-05-29 |
Kite Pharma, Inc. |
Chimeric polypeptides and uses thereof
|
|
KR20250114570A
(ko)
|
2017-09-22 |
2025-07-29 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 이중특이적 폴리펩티드 복합체
|
|
CN107759699A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd30抗原的转基因t细胞及其制备方法与应用
|
|
CN107759700A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd19抗原的转基因t细胞及其制备方法与应用
|
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
US12258580B2
(en)
|
2017-11-01 |
2025-03-25 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
|
KR20200097253A
(ko)
|
2017-11-01 |
2020-08-18 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 조성물의 생산방법
|
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
KR20200076732A
(ko)
|
2017-11-03 |
2020-06-29 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Cd38-지시된 키메라 항원 수용체 작제물
|
|
US11826385B2
(en)
*
|
2017-11-10 |
2023-11-28 |
Jura Bio, Inc. |
Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
|
|
WO2019109053A1
(en)
|
2017-12-01 |
2019-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
|
WO2019112347A2
(ko)
*
|
2017-12-06 |
2019-06-13 |
앱클론(주) |
악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
|
|
MX2020005908A
(es)
|
2017-12-08 |
2020-10-07 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t modificadas.
|
|
AU2018379094B2
(en)
|
2017-12-08 |
2025-09-25 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
|
WO2019113556A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
WO2019125070A1
(ko)
*
|
2017-12-22 |
2019-06-27 |
앱클론(주) |
악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
|
|
CN107903326B
(zh)
*
|
2018-01-02 |
2020-06-30 |
广东省人民医院(广东省医学科学院) |
包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
|
|
CN108047332B
(zh)
*
|
2018-01-15 |
2021-08-24 |
阿思科力(苏州)生物科技有限公司 |
以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
WO2019152743A1
(en)
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
WO2019155288A1
(en)
|
2018-02-09 |
2019-08-15 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
SI3752501T1
(sl)
|
2018-02-13 |
2023-08-31 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
|
EA202091982A1
(ru)
*
|
2018-03-14 |
2021-06-10 |
Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) |
Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии
|
|
EP3765070A4
(en)
*
|
2018-03-14 |
2021-12-15 |
Dana-Farber Cancer Institute, Inc. |
SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
BR112020020887A2
(pt)
|
2018-04-12 |
2021-04-06 |
Umoja Biopharma, Inc |
Vetores virais e linhagens celulares de empacotamento
|
|
AR114789A1
(es)
*
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
CA3093130C
(en)
|
2018-04-19 |
2023-10-17 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
CA3098497A1
(en)
|
2018-05-03 |
2019-11-07 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
EP3790591A4
(en)
*
|
2018-05-09 |
2022-05-11 |
LegoChem Biosciences, Inc. |
Compositions and methods related to anti-cd19 antibody drug conjugates
|
|
DK3793565T3
(en)
|
2018-05-14 |
2022-03-07 |
Gilead Sciences Inc |
Mcl-1-inhibitorer
|
|
SI3820572T1
(sl)
|
2018-07-13 |
2023-12-29 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
|
JP7560882B2
(ja)
|
2018-08-29 |
2024-10-03 |
ナショナル ユニヴァーシティー オブ シンガポール |
遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
|
|
EP3856763A1
(en)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
JP7158577B2
(ja)
|
2018-10-24 |
2022-10-21 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｐｄ－１／ｐｄ－ｌ１阻害剤
|
|
CA3117556A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
CA3117568A1
(en)
|
2018-10-31 |
2020-05-07 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
CA3117720A1
(en)
|
2018-11-06 |
2020-05-14 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
SG11202104631SA
(en)
*
|
2018-11-07 |
2021-06-29 |
Crispr Therapeutics Ag |
Anti-ptk7 immune cell cancer therapy
|
|
JP2022513062A
(ja)
|
2018-11-16 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法
|
|
KR20210110811A
(ko)
|
2018-11-30 |
2021-09-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
|
|
KR20210117260A
(ko)
|
2018-11-30 |
2021-09-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료방법
|
|
WO2020114358A1
(zh)
*
|
2018-12-03 |
2020-06-11 |
广东东阳光药业有限公司 |
Cd19抗体及其应用
|
|
CN120025452A
(zh)
|
2018-12-12 |
2025-05-23 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
|
CN109734813B
(zh)
*
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
WO2020162452A1
(ja)
*
|
2019-02-04 |
2020-08-13 |
国立大学法人愛媛大学 |
ＣＡＲライブラリおよびｓｃＦｖの製造方法
|
|
WO2020172440A1
(en)
|
2019-02-20 |
2020-08-27 |
Qin Hong |
Baff-r/cd19 targeted chimeric antigen receptor-modified t cells and use thereof
|
|
BR112021017537A2
(pt)
|
2019-03-05 |
2021-12-14 |
Nkarta Inc |
Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
JP7350871B2
(ja)
|
2019-03-07 |
2023-09-26 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
２’３’－環状ジヌクレオチドおよびそのプロドラッグ
|
|
WO2020191336A1
(en)
|
2019-03-21 |
2020-09-24 |
Yamaguchi, Yukiko |
Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
JP2022537700A
(ja)
|
2019-06-12 |
2022-08-29 |
ジュノー セラピューティクス インコーポレイテッド |
細胞媒介細胞傷害性療法と生存促進性ｂｃｌ２ファミリータンパク質の阻害剤との併用療法
|
|
WO2020253879A1
(zh)
*
|
2019-06-21 |
2020-12-24 |
甘李药业股份有限公司 |
一种双特异性嵌合抗原受体
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
CN112210007B
(zh)
*
|
2019-07-11 |
2022-07-12 |
华夏英泰（北京）生物技术有限公司 |
一种cd19抗原高亲和力的抗体以及包含其cd19单链抗体区的嵌合抗原受体
|
|
WO2021016062A1
(en)
*
|
2019-07-19 |
2021-01-28 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
|
EP3769816A1
(en)
*
|
2019-07-25 |
2021-01-27 |
Ospedale Pediatrico Bambino Gesù |
Car-cd123 vector and uses thereof
|
|
JP2022545467A
(ja)
|
2019-08-22 |
2022-10-27 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
|
|
KR20210028544A
(ko)
|
2019-09-04 |
2021-03-12 |
주식회사 레고켐 바이오사이언스 |
인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
EP4038194A1
(en)
|
2019-10-04 |
2022-08-10 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
US11795223B2
(en)
|
2019-10-18 |
2023-10-24 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
MX2022005145A
(es)
|
2019-10-30 |
2022-06-29 |
Juno Therapeutics Gmbh |
Dispositivos de estimulación y/o selección celular y método de uso.
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
WO2021084064A1
(en)
*
|
2019-10-31 |
2021-05-06 |
Morphosys Ag |
Sequential anti-cd19 therapy
|
|
BR112022007548A2
(pt)
|
2019-11-07 |
2022-07-12 |
Juno Therapeutics Inc |
Combinação de uma terapia de célula t e (s)-3-[4-(4-morfolin-4-ilmetil-benzilóxi)-1-oxo-1,3-di-hidro-isoindol-2-il]-piperidina-2,6-diona
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
KR20220132527A
(ko)
|
2019-12-06 |
2022-09-30 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ 세포 악성 종양을 치료하기 위한 세포 요법과 연관된 독성 및 반응과 관련된 방법
|
|
MX2022007930A
(es)
|
2019-12-24 |
2022-08-08 |
Carna Biosciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
IL294715A
(en)
|
2020-01-23 |
2022-09-01 |
Childrens Medical Ct Corp |
Stroma-free t cell differentiation from human pluripotent stem cells
|
|
WO2021151008A1
(en)
|
2020-01-24 |
2021-07-29 |
Juno Therapuetics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
|
JP2023512209A
(ja)
|
2020-01-28 |
2023-03-24 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞形質導入のための方法
|
|
MX2022009832A
(es)
|
2020-02-12 |
2023-02-14 |
Juno Therapeutics Inc |
Composiciones de celulas t de receptor de antigeno quimerico dirigido a cd19 y usos de las mismas.
|
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
BR112022017924A2
(pt)
|
2020-03-10 |
2022-12-20 |
Massachusetts Inst Technology |
Composições e métodos para imunoterapia de câncer npm1c-positivo
|
|
WO2021183675A2
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
EP4143194A1
(en)
|
2020-05-01 |
2023-03-08 |
Gilead Sciences, Inc. |
Cd73 inhibiting 2,4-dioxopyrimidine compounds
|
|
JP7727662B2
(ja)
|
2020-05-13 |
2025-08-21 |
ジュノー セラピューティクス インコーポレイテッド |
臨床応答に関連する特徴量の特定方法およびその使用
|
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
|
|
WO2022010847A1
(en)
|
2020-07-07 |
2022-01-13 |
Cancure, Llc |
Mic antibodies and binding agents and methods of using the same
|
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
US20230406922A1
(en)
|
2020-11-20 |
2023-12-21 |
Simcere Zaiming Pharmaceutical Co., Ltd. |
Humanized cd19 antibody and use thereof
|
|
IL302744A
(en)
|
2020-11-24 |
2023-07-01 |
Lyell Immunopharma Inc |
Methods for production, total preparations and methods of using regenerated T cells
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
EP4263600A1
(en)
|
2020-12-18 |
2023-10-25 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
AU2021413365A1
(en)
|
2020-12-30 |
2023-07-20 |
Precigen, Inc. |
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
|
|
KR20230151513A
(ko)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Cd8 표적 바이러스 벡터의 용도
|
|
EP4301755A1
(en)
|
2021-03-03 |
2024-01-10 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
JP2024511420A
(ja)
|
2021-03-22 |
2024-03-13 |
ジュノー セラピューティクス インコーポレイテッド |
ウイルスベクター粒子の効力を評価する方法
|
|
EP4314814A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
IL307257A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
|
|
EP4313127A1
(en)
|
2021-03-29 |
2024-02-07 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
US20250283037A1
(en)
|
2021-05-06 |
2025-09-11 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
EP4359389A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117616048A
(zh)
*
|
2021-07-09 |
2024-02-27 |
先声再明医药有限公司 |
Cd19抗体及其应用
|
|
EP4370541A1
(en)
|
2021-07-14 |
2024-05-22 |
2seventy bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
EP4381050A4
(en)
*
|
2021-08-06 |
2025-10-08 |
Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute |
T CELL MANUFACTURING PROCESSES
|
|
MX2024003813A
(es)
*
|
2021-10-18 |
2024-04-25 |
Kite Pharma Inc |
Dominios de se?alizacion para receptores de antigeno quimerico.
|
|
CA3234909A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP2024541979A
(ja)
|
2021-10-29 |
2024-11-13 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
TW202342498A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科融合醣蛋白
|
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
KR20240125012A
(ko)
|
2021-12-22 |
2024-08-19 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
US20250101379A1
(en)
|
2022-01-28 |
2025-03-27 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
DK4245756T3
(da)
|
2022-03-17 |
2024-10-21 |
Gilead Sciences Inc |
Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf
|
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
WO2023192321A2
(en)
*
|
2022-03-28 |
2023-10-05 |
Vygen-Bio, Inc. |
Genetically engineered antibody resistant (gear) cells for adoptive cellular therapy
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
JP2025511872A
(ja)
|
2022-04-08 |
2025-04-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多部位受容体及びシグナル伝達複合体
|
|
CN114716558B
(zh)
*
|
2022-04-12 |
2023-05-05 |
骏蓦(北京)生物科技有限公司 |
一种双特异性抗体及其治疗癌症的应用
|
|
IL316058A
(en)
|
2022-04-21 |
2024-11-01 |
Gilead Sciences Inc |
Compounds modulate KRAS G12D
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
WO2023225569A1
(en)
|
2022-05-17 |
2023-11-23 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
EP4547230A1
(en)
|
2022-06-29 |
2025-05-07 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
CR20240570A
(es)
|
2022-07-01 |
2025-03-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
TW202434735A
(zh)
|
2022-11-04 |
2024-09-01 |
美商烏莫賈生物製藥股份有限公司 |
展示黏著分子融合的顆粒
|
|
EP4612309A2
(en)
|
2022-11-04 |
2025-09-10 |
Umoja Biopharma, Inc. |
Lentiviral particles displaying fusion molecules and uses thereof
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
AR131320A1
(es)
|
2022-12-13 |
2025-03-05 |
Juno Therapeutics Inc |
Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
|
|
KR20250122479A
(ko)
|
2022-12-22 |
2025-08-13 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
IL322815A
(en)
|
2023-02-28 |
2025-10-01 |
Juno Therapeutics Inc |
Cell therapy for the treatment of systemic autoimmune diseases
|
|
CN120641113A
(zh)
|
2023-03-31 |
2025-09-12 |
西比曼生物科技集团 |
靶向cd20和bcma的双特异性嵌合抗原受体
|
|
US20240383922A1
(en)
|
2023-04-11 |
2024-11-21 |
Gilead Sciences, Inc. |
KRAS Modulating Compounds
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220588A1
(en)
|
2023-04-18 |
2024-10-24 |
Juno Therapeutics, Inc. |
Cytotoxicity assay for assessing potency of therapeutic cell compositions
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
AU2024259556A1
(en)
|
2023-04-21 |
2025-10-23 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024226858A1
(en)
|
2023-04-26 |
2024-10-31 |
Juno Therapeutics, Inc. |
Methods for viral vector manufacturing
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250100998A1
(en)
|
2023-07-26 |
2025-03-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025231174A1
(en)
|
2024-04-30 |
2025-11-06 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
WO2025235604A1
(en)
|
2024-05-08 |
2025-11-13 |
Umoja Biopharma, Inc. |
Fusion protein for use as immune cell engager
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|